Plasminogen activation and cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Plasminogen activation and cancer. / Danø, Keld; Behrendt, N.; Hoyer-Hansen, G.; Johnsen, Morten; Lund, L. R.; Ploug, Michael; Nielsen, John Rømer.
I: Thrombosis and Haemostasis, Bind 93, Nr. 4, 2005, s. 676-681.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasminogen activation and cancer
AU - Danø, Keld
AU - Behrendt, N.
AU - Hoyer-Hansen, G.
AU - Johnsen, Morten
AU - Lund, L. R.
AU - Ploug, Michael
AU - Nielsen, John Rømer
PY - 2005
Y1 - 2005
N2 - Breakdown of the extracellular matrix is crucial for cancer invasion and metastasis. It is accomplished by the concerted action of several proteases, including the serine protease plasmin and a number of matrix metalloproteases.The activity of each of these proteases is regulated by an array of activators, inhibitors and cellular receptors.Thus, the generation of plasmin involves the pro-enzyme plasminogen, the urokinase type plasminogen activator uPA and its pro-enzyme pro-uPA, the uPA inhibitor PAI-1, the cell surface uPA receptor uPAR, and the plasmin inhibitor a2 -antiplasmin. Furthermore, the regulation of extracellular proteolysis in cancer involves a complex interplay between cancer cells and non-malignant stromal cells in the expression of the molecular components involved. For some types of cancer, this cellular interplay mimics that observed in the tissue of ori- gin during non-neoplastic tissue remodelling processes.We propose that cancer invasion can be considered as uncontrolled tissue remodelling. Inhibition of extracellular proteases is an attractive approach to cancer therapy. Because proteases have many different functions in the normal organism, efficient inhibition will have toxic side effects.In cancer invasion, like in normal tissue remodelling processes, there appears to be a functional overlap between different extracellular proteases.This redundancy means that combinations of protease inhibitors must be used. Such combination therapy, however, is also likely to increase toxicity.Therefore for each type of cancer, a combination of protease inhibitors that is optimised with respect to both maximal therapeutic effect and minimal toxic side effects need to be identified.
AB - Breakdown of the extracellular matrix is crucial for cancer invasion and metastasis. It is accomplished by the concerted action of several proteases, including the serine protease plasmin and a number of matrix metalloproteases.The activity of each of these proteases is regulated by an array of activators, inhibitors and cellular receptors.Thus, the generation of plasmin involves the pro-enzyme plasminogen, the urokinase type plasminogen activator uPA and its pro-enzyme pro-uPA, the uPA inhibitor PAI-1, the cell surface uPA receptor uPAR, and the plasmin inhibitor a2 -antiplasmin. Furthermore, the regulation of extracellular proteolysis in cancer involves a complex interplay between cancer cells and non-malignant stromal cells in the expression of the molecular components involved. For some types of cancer, this cellular interplay mimics that observed in the tissue of ori- gin during non-neoplastic tissue remodelling processes.We propose that cancer invasion can be considered as uncontrolled tissue remodelling. Inhibition of extracellular proteases is an attractive approach to cancer therapy. Because proteases have many different functions in the normal organism, efficient inhibition will have toxic side effects.In cancer invasion, like in normal tissue remodelling processes, there appears to be a functional overlap between different extracellular proteases.This redundancy means that combinations of protease inhibitors must be used. Such combination therapy, however, is also likely to increase toxicity.Therefore for each type of cancer, a combination of protease inhibitors that is optimised with respect to both maximal therapeutic effect and minimal toxic side effects need to be identified.
U2 - 10.1160/TH05-01-0054
DO - 10.1160/TH05-01-0054
M3 - Journal article
VL - 93
SP - 676
EP - 681
JO - Thrombosis et diathesis haemorrhagica
JF - Thrombosis et diathesis haemorrhagica
SN - 0340-6245
IS - 4
ER -
ID: 1093574